A single trophectoderm biopsy at blastocyst stage is mathematically unable to determine embryo ploidy accurately enough for clinical use

Norbert Gleicher, Jacob Metzger, Gist Croft, Vitaly A Kushnir, David F Albertini, David H Barad, Norbert Gleicher, Jacob Metzger, Gist Croft, Vitaly A Kushnir, David F Albertini, David H Barad

Abstract

Background: It has become increasingly apparent that the trophectoderm (TE) at blastocyst stage is much more mosaic than has been appreciated. Whether preimplantation genetic screening (PGS), utilizing a single TE biopsy (TEB), can reliably determine embryo ploidy has, therefore, increasingly been questioned in parallel.

Methods: We for that reason here established 2 mathematical models to assess probabilities of false-negative and false-positive results of an on average 6-cell biopsy from an approximately 300-cell TE. This study was a collaborative effort between investigators at The Center for Human Reproduction in New York City and the Center for Studies in Physics and Biology and the Brivanlou Laboratory of Stem Cell Biology and Molecular Embryology, the latter two both at Rockefeller University in New York City.

Results: Both models revealed that even under best case scenario, assuming even distribution of mosaicism in TE (since mosaicism is usually clonal, a highly unlikely scenario), a biopsy of at least 27 TE cells would be required to reach minimal diagnostic predictability from a single TEB.

Conclusions: As currently performed, a single TEB is, therefore, mathematically incapable of reliably determining whether an embryo can be transferred or should be discarded. Since a single TEB, as currently performed, apparently is not representative of the complete TE, this study, thus, raises additional concern about the clinical utilization of PGS.

Keywords: In vitro fertilization; Mathematical model; Premplantation genetic screening; Trophectoderm biopsy.

Figures

Fig. 1
Fig. 1
Schematics of PGS. The currently in use PGS procedure (PGS 2.0) is based on a single TEB of on average approximately 6 cells, which is alleged to accurately reflect the chromosomal status of the developing embryo/fetus. The procedure has entered worldwide clinical use without prior clinical validation. Three crucial questions (unresolved issues in the figure) still require resolution. This manuscript attempts to answer the first of these questions, whether a single TEB accurately enough reflects the whole TE to discriminate between embryos that can undergo transfer and those that should be discarded
Fig. 2
Fig. 2
P-values for observing no mosaicism, given different hypotheses r and a threshold of 0,05 (dotted line). With the curve crossing the significance line (P = 0.05) at 0.6, the figure demonstrates that any value of r larger than 60% euploid cells leads to a P-value that is larger than the usual significance level of 5% (indicated as a dashed line in the figure), meaning that even the hypothesis that there are 40% aneuploid cells in the embryo cannot be rejected when not observing any aneuploid cells in the biopsy
Fig. 3
Fig. 3
P-values for observed mosaicism, given different hypotheses r, and varying numbers of abnormal-aneuploid cells in biopsy. The curves demonstrate that, even when obtaining a mosaic TEB, with decreasing aneuploidy cell numbers in the TEB (from 6 to 1), any explanation with increasing r from r < 0.4 to r < 0.99 could be a reasonable explanation of the observed data since it leads to observing mosaicism in >5% of cases. The threshold at which r crosses the significance level increases with decreasing aneuploidy. This means that a given r is more likely to explain the obtained biopsy result the lower the measured aneuploidy is. For example, if one (or more) cells are aneuploid, the threshold will be approximately r = 0.99, meaning that even a hypothesis of r = 0.99, basically an entirely euploid embryo, is compatible with the data. On the other hand, if three (or more) cells are aneuploid, a hypothesis with an r as high 0.99 is too unlikely to give the observed data, and only an r < 0.85 hypothesis is compatible with this biopsy outcome

References

    1. Gleicher N, Kushnir VA, Barad DH. Is it time for a paradigm shift in understanding embryo selection? Reprod Biol Endocrinol. 2015;13:3. doi: 10.1186/1477-7827-13-3.
    1. Sermon K, Capalbo A, Cohen J, Coonen E, De Rycke M, De Vos A, Delhanty J, Florentino F, Gleicher N, Griesinger G, Grifo J, Handyside A, Harper J, Kokkali G, Mastenbroek S, Meldrum D, Meseguer M, Montag M, Munné S, Rienzi L, Rubio C, Scott K, Scott R, Simon C, Swain J, Treff N, Ubaldi F, Vassena R, Vermeesch JR, Verpoest W, Wells D, Geraedtts J. The why, the how and when of PGS 2.0: current practices and expert opinions of fertility specialists, molecular biologists and embryologists. Mol Hum Reprod. 2016;22:845–57. doi: 10.1093/molehr/gaw034.
    1. Gleicher N, Barad D. A review of, and commentary on the ongoing second clinical introduction of preimplantation genetic screening (PGS) to routine IVF practice. J Assist Reprod Genet. 2012;29(11):1159–66. doi: 10.1007/s10815-012-9871-2.
    1. Gleicher N, Kushnir VA, Barad DH. Preimplantation genetic screening (PGS) still in search of a clinical application: a systematic review. Reprod Biol Endocrinol. 2014;15:12–22.
    1. Twisk M, Mastenbroek S, van Wely M, Heineman MJ, Van der Veen F, Repping S. Preimplantation genetic screening for abnormal number of chromosomes (aneuploidies) in in vitro fertilisation or intracytoplasmic sperm injection. Cochrane Database Syst Rev. 2006;25(1):CD005291.
    1. Mastenbroek S, Twisk M, van Echten-Arnds J, Sikkema-Raddatz B, Korevaar JC, Verhoeve HR, Vogel NE, Arts EG, de Vries JW, Bossuyr PM, Buys CH, Heineman MJ, Reppings S, van der Veen F. In vitro fertilization with preimplantation genetic screening. N Engl J Med. 2007;357(1):9–17. doi: 10.1056/NEJMoa067744.
    1. Mastenbroek S, Twisk M, van der Veen F, Repping S. Preimplantation genetic screening: a systematic review and meta-analysis of RCTs. Hum Reprod Update. 2011;17(4):454–66. doi: 10.1093/humupd/dmr003.
    1. Gleicher N, Weghofer A, Barad D. Preimplantation genetic screening: “established” and ready for prime time? Fertil Steril. 2008;89:780–8. doi: 10.1016/j.fertnstert.2008.01.072.
    1. Mastenbroek S, Repping S. Preimplantation genetic screening: back to the future. Hum Reprod. 2014;29(9):1846–50. doi: 10.1093/humrep/deu163.
    1. Orvieto R, Shuly Y, Brengauz M, Feldman B. Should preimplantation genetic screening be implemented to routine clinical practice? Gynecol Endocrinol. 2016;32:506–8. doi: 10.3109/09513590.2016.1142962.
    1. Gleicher N, Vidali A, Braverman J, Kushnir VA, Barad DH, Hudson C, Wu YG, Wang Q, Zhang L, Albertini DF. Accuracy of preimplantation genetic screening (PGS) is compromised by degree of mosaicism of human embryos. Reprod Biol Endocrinol. 2016;14:54. doi: 10.1186/s12958-016-0193-6.
    1. Bolton H, Graham SJL, Van der Aa N, Kumar P, Theunis K, Gallardo EF, Voet T, Zernicka-Goetz M. Mouse model of chromosome mosaicism reveals lineage-specific depletion of aneuploid cells and normal development potential. Nat Commun. 2016;7:11165. doi: 10.1038/ncomms11165.
    1. Gleicher N, Vidali A, Braverman J, Kushnir VA, Albertini DF, Barad DH. Further evidence against use of PGS in poor prognosis patients: report of normal births after transfer of embryos reported as aneuploid. Fertil Steril. 2015;104(Suppl 3):e9.
    1. Greco E, Minasi G, Fiorentino F. Healthy babies after intrauterine transfer of mosaic aneuploid blastocysts. N Engl J Med. 2015;373:2089–90. doi: 10.1056/NEJMc1500421.
    1. PGDIS Newsletter, PGDIS Position Statement on Chromosome Mosaicism and Preimplantation Aneuploidy Testing at the Blastocyst Stage, Chicago, Illinois, July 19, 2016. . Accessed 12 Feb 2017.
    1. Simpson JL. Guest Editorial. Preimplantation genetic diagnosis: its time is now. Contemp ObGyn 2016; ; July 2016. Accessed 12 Feb 2017.
    1. Deglincerti A, Coft GE, Pietila LN, Zernicka-Goetz M, Siggia ED, Brivanlou AH. Self-organization of the in vitro attached human embryo. Nature. 2016;533(7602):251–4. doi: 10.1038/nature17948.
    1. Hardy K, Stark J, Winston RML. Maintenance of the inner cell mass in human blastocysts from fragmented embryos. Biol Reprod. 2002;68:1165–9. doi: 10.1095/biolreprod.102.010090.
    1. Lee A, Kiessling AA. Early human embryos are naturally aneuploid-can that be corrected? J Assist Reprod Genet. 2017; doi:10.1007/s10815-016-0845-7.
    1. Liu E, Escudero T, Ribustello L, Baukman K, Colls P, Munné S. Chromosome abnormalities detected by array comparative genomic hybridization and next-generation sequencing: results on >38,000 embryos. 2016. p. 601.
    1. Capalbo A, Ubaldi FM, Cimadomo D, Maggiulli R, Patassini C, Dusi L, Sanges F, Buffo L, Venturella R, Rienzi L. Consistent and reproducible outcomes of blastocyst biopsy and aneuploidy screening across different biopsy practitioners: a multicentre study involving 2586 embryo biopsies. Hum Reprod. 2016;31(1):199–208. doi: 10.1093/humrep/dev294.
    1. Munné S, Wells D, Cohen J. Technology requirements for preimplantation genetic diagnosis to improve assisted reproduction outcomes. Fertil Steril. 2010;94:408–30. doi: 10.1016/j.fertnstert.2009.02.091.
    1. Albertini DE. On the dichotomy (im)posed by developmental autonomy during early human embryogenesis. J Assist Reprod Genet. 2016;33(7):821–2. doi: 10.1007/s10815-016-0758-5.
    1. Maheshwari A, Hamilton M, Bhattacharva S. Should we be promoting embryo transfer at blastocyst stage? Reprod Biomed Online. 2016;32(2):1420146.
    1. Fritz MA. Perspectives on the efficacy and indications for preimplantation genetic screening: where are we now? Hum Reprod. 2008;23:2617–21. doi: 10.1093/humrep/den400.
    1. ACOG Committee Opinion No. 430 Preimplantation genetic screening for aneuploidy. Obstet Gynecol. 2009;113:766–7. doi: 10.1097/AOG.0b013e31819e9f05.
    1. American Society for Reproductive Medicine Preimplantation genetic testing: a Practice Committee opinion. Fertil Steril. 2008;90:S136–43.
    1. Harton G, Braude P, Lashwood A, et al. ESHRE PGD consortium best practice guidelines for organization of a PGD centre for PGD/preimplantation genetic screening. Hum Reprod. 2011;26:14–24. doi: 10.1093/humrep/deq229.
    1. Fiorentino F, Biricick A, Bono S, Greco E, Minasi MG, Ruberti A, Spinella F. Clinical outcome derived after transfer of embryos with chromosomal mosaicism, Abstracts of the 32nd Annual Meeting of ESHRE, Helsinki, Finland, July3-6. 2016. p. O–028.
    1. Garrisi GJ, Walmsley R, Bauckman K, Mendola R, Colls P, Munné S. A small trophectoderm biopsy sample is sufficient to detect most mosaicism after analysis with high resolution next generation sequencing (NGS) 2016. p. 642.
    1. Kushnir VA, Darmon SK, Albertini DF, Barad DH, Gleicher N. Effectiveness of in vitro fertilization with preimplantation genetic screening: a reanalysis of United States assisted reproductive technology data 2011–2012. Fertil Steril. 2016;106(1):75–9. doi: 10.1016/j.fertnstert.2016.02.026.
    1. Fragouli E, Alfarawati S, Spath K, Tarozzi N, Borini A, Wells D. The developmental potential of mosaic embryos. Fertil Steril. 2015;104(Suppl 3):e96. doi: 10.1016/j.fertnstert.2015.07.297.
    1. Joyner MJ, Paneth N, Ioannidis JPA. What happens when underperforming big ideas in research become entrenched? JAMA. 2016;316:1355–6. doi: 10.1001/jama.2016.11076.

Source: PubMed

3
Tilaa